{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-002790","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2022-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.068661+00:00","generated_at":"2026-06-26T04:43:10.675863+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Compass Therapeutics appoints Chiniara and Gray to board; Toledano departs","bullets":["Ellen Chiniara (former Alexion Chief Legal Officer) and Mary Ann Gray (Gray Strategic Advisors) join as Class I directors.","Both deemed independent; Chiniara also appointed to Nominating/Governance and Compensation committees.","Each non-employee director receives $45K cash retainer and initial option on 45,000 shares vesting over four years.","Miranda Toledano will not stand for reelection at May 24, 2022 annual meeting; no disagreement cited.","Appointments aim to support pipeline advancement and shareholder value creation."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-002790","json":"https://secwatch.observer/filing/0001171843-22-002790.json","markdown":"https://secwatch.observer/filing/0001171843-22-002790.md","text":"https://secwatch.observer/filing/0001171843-22-002790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002790/0001171843-22-002790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002790/f8k_042522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:43:10.675863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"465cad7b65","claim":"Miranda Toledano departed as Director at Compass Therapeutics, Inc..","evidence_excerpt":"On April 22, 2022, Miranda Toledano, M.B.A., a member of the Board of the Company, notified the Company that she is declining to stand for reelection to the Board at the completion of her current term, ending at the Company’s Annual Meeting of Stockholders set for May 24, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002790/0001171843-22-002790-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"declined to stand for reelection"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"97a6e8c9db","claim":"Ellen Chiniara was appointed as Director at Compass Therapeutics, Inc..","evidence_excerpt":"On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002790/0001171843-22-002790-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"b7311ff613","claim":"Mary Ann Gray was appointed as Director at Compass Therapeutics, Inc..","evidence_excerpt":"On April 25, 2022, the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed two new directors to its Board: Ellen Chiniara, J.D., former Chief Legal Officer of Alexion Pharmaceuticals; and Mary Ann Gray, Ph.D., President of Gray Strategic Advisors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002790/0001171843-22-002790-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}